| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | CCTS | Class A ordinary shares | 3.16M | Oct 28, 2021 | Direct | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | The shares reported hereby are Class A ordinary shares that are issuable on a one-for-one basis upon automatic conversion of an equivalent number of Class B ordinary shares beneficially owned by the Reporting Persons, which conversion will occur upon consummation of the Issuer's initial business combination. Class B ordinary shares and Class A ordinary shares are generally entitled to identical economic and voting rights, with certain limited exceptions, and are therefore treated as a single class for purposes hereof. |
| F2 | Up to 412,500 of the 3,162,500 shares reported herein were subject to forfeiture to the extent the underwriters for the Issuer's initial public offering would not exercise their over-allotment option for that offering by December 12, 2021. The underwriters fully exercised that over-allotment option, so there was no forfeiture of any shares reported herein. |
| F3 | The shares reported in this row are held of record by Cactus Healthcare Management LP (the "Cactus sponsor"). Cactus Healthcare Management LLC (the "Cactus sponsor GP") serves as the sole general partner of the Cactus sponsor and directs voting and investment decisions made by the Cactus sponsor with respect to the subject shares. The Cactus sponsor GP is owned equally by Hibotan LLC (an affiliate of Israel Biotech Fund), Kalistcare Limited (an affiliate of Consensus Business Group) and Clal Biotechnology Industries Cactus Ltd. (an affiliate of Clal Biotechnology Industries Ltd.), each of which holds a 33.33% equity interest in the Cactus sponsor GP. The Cactus sponsor GP does not possess a pecuniary interest with respect to the subject shares and therefore disclaims beneficial ownership thereof. |